To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
All the news of the Institute of life sciences Frédéric Joliot
European ＆ international partnerships
Involvement of the Institute of life sciences Frédéric Joliot in EU programmes.
Creating the first European clinical trials network for autism, AIMS-2-TRIALS aims to improve outcomes for people with
ASD (precision medicine). To do this it will create a pipeline for developing,
testing and implementing new treatments for ASD with stakeholder involvement at
each stage. The project will set up a global clinical trial network for ASD to
validate biological markers and endpoints to reliably show whether or not a
treatment is effective and appropriate for ASD. Within this precision medicine
project coordinated by the King’s College, CEA’s team
will perform genetic imaging studies.
The consortium PEVIA aims to develop a new generation of vaccines against multiple strains of Ebola virus, easily produced and deployed in endemic areas. This will improve the effectiveness of the vaccine against various strains of a mutant virus to provide lasting protection against multiple exposures to the Ebola virus. In addition, our vaccine will not require low temperature storage (+4 to +8 ° C), overcoming stability and storage issues in endemic areas, and enabling rapid deployment in the field.
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.